Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
This was a primary data collection-based special drug-use surveillance to be conducted in accordance with the GPSP ordinance.
Observational period lasted 24 months from the start of treatment with Kesimpta.
Age
0–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients must provide written consent to cooperate in this study before the start of treatment with Kesimpta
2. Patients using Kesimpta for the first time for the following indication Indication: prevention of relapses and and prevention of physical disability progression in the following patients
* Relapsing-remitting MS
* Active SPMS
You may not be if
1. Patients with a history of treatment with a drug containing the same ingredient as Kesimpta (investigational drug or post-marketing clinical study drug)
2. Patients with a history of hypersensitivity to any of the Kesimpta ingredients
